Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis

(2016) Tatiana Plavina et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Body weight-based natalizumab treatment in adult patients with multiple sclerosis

(2015) M. Tanaka et al.   JOURNAL OF NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

(2012) Anke Vennegoor et al.   Multiple Sclerosis Journal

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Review: Natalizumab in the treatment of multiple sclerosis

(2009) Özgür Yaldizli et al.   Therapeutic Advances in Neurological Disorders

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS